Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0UNENK
ADC Name
US12144865B2 35k
Synonyms
US12144865B2 35k
   Click to Show/Hide
Organization
BAYER PHARMA AKTIENGESELLSCHAFT
Drug Status
Investigative
Drug-to-Antibody Ratio
3.5
Structure
Antibody Name
TPP-2658
  Antibody Info 
Antigen Name
Tumor necrosis factor receptor superfamily member 12A (TNFRSF12A)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
Undisclosed
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal inhibitory Concentration (IC50)Human PBMC 
0.286
nM
CVCL_0399
Colon adenocarcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
16.5
nM
CVCL_0186
Pancreatic ductal adenocarcinoma
Half Maximal inhibitory Concentration (IC50)Human PBMC 
22.9
nM
CVCL_0455
Lung mucoepidermoid carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 0.286 nM Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description
Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model Colon adenocarcinoma LoVo cells CVCL_0399
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 16.5 nM Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description
Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model Pancreatic ductal adenocarcinoma BxPC-3 cells CVCL_0186
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal inhibitory Concentration (IC50)Human PBMC 22.9 nM Positive TNFRSF12A expression (TNFRSF12A+++/++)
Method Description
Tables 1b and 1c below set out the IC50 values for representative working examples from this assay
In Vitro Model Lung mucoepidermoid carcinoma NCI-H292 cells CVCL_0455
References
Ref 1 Antibody drug conjugates with enzymatically cleavable groups